Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-GRFT Nasal Spray for COVID-19 Prophylaxis
NCT05180500Phase 1Completed
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing Q-GRFT Nasal Spray with Placebo Nasal Spray (2 arms). Primary endpoint: Number of Participants With Related Grade 2 or Higher Adverse Events at 8 weeks. Started Mar 2022; status: completed.
02
Drugs
q-griffithsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05180500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180500.